Skip Navigation

Cardiovascular Research 2003 58(3):655-662; doi:10.1016/S0008-6363(03)00333-X
© 2003 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schäfer, A.
Right arrow Articles by Bauersachs, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schäfer, A.
Right arrow Articles by Bauersachs, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2003, European Society of Cardiology

Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction

Andreas Schäfera, Daniela Fraccarolloa, Steven K Hildemannb, Piet Tasc, Georg Ertla and Johann Bauersachsa,*

aMedizinische Klinik der Julius-Maximilians-Universität Würzburg, Josef-Schneider-Str. 2, D-97080 Würzburg, Germany
bPharmacia Corp., Peapack, NJ, USA
cKlinik für Anaesthesiologie der Julius-Maximilians-Universität Würzburg, Würzburg, Germany

bauersachs_j{at}medizin.uni-wuerzburg.de

* Corresponding author. Tel.: +49-931-2011; fax: +49-931-2013-6302.

Objectives: To investigate the effects of adding the selective aldosterone receptor antagonist eplerenone to ACE inhibition on endothelium-dependent vasodilation in rats with chronic heart failure (CHF). Background: Addition of the non-selective aldosterone antagonist spironolactone to ACE-inhibitors reduces mortality and morbidity in CHF and improves endothelial vasomotor dysfunction, but is associated with considerable side-effects. Methods: Starting 10 days after extensive myocardial infarction (MI) or sham-operation, Wistar rats were treated either with placebo, the ACE inhibitor trandolapril (TR, 0.3 mg/kg body weight per day), the selective aldosterone receptor antagonist eplerenone (EPL, 100 mg/kg per day) or a combination of both for 9 weeks. Results: Maximum acetylcholine-induced, nitric oxide-dependent relaxation was significantly attenuated in aortic rings from rats with CHF compared with sham-operated animals (Rmax 55% vs. 87%). EPL alone slightly and TR significantly improved NO-mediated relaxation (CHF-EPL 66%; CHF-TR: 78%), while treatment with both EPL and TR completely restored endothelium-dependent vasorelaxation (CHF-EPL-TR: 83%). Aortic superoxide formation was significantly increased in rats with CHF compared with sham-operated animals, but was normalised by treatment with EPL or TR-EPL. Expression of the endothelial nitric oxide synthase was decreased in CHF and normalised in all treatment groups. Conclusions: In experimental CHF, the selective aldosterone antagonist EPL reduced the increased vascular superoxide formation. Although a combination of TR and EPL normalised endothelium-dependent relaxation, ACE inhibition as a monotherapy was almost equally effective.

KEYWORDS Endothelial function; Myocardial infarction; Heart failure; ACE inhibitors; Aldosterone


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur J Heart FailHome page
A. Schafer, D. Fraccarollo, J. Widder, M. Eigenthaler, G. Ertl, and J. Bauersachs
Inhibition of platelet activation in rats with severe congestive heart failure by a novel endothelial nitric oxide synthase transcription enhancer
Eur J Heart Fail, April 1, 2009; 11(4): 336 - 341.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, C. Monteil, V. Richard, S. Renet, J. P. Henry, A. Y. Jeng, et al.
Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone
Eur. Heart J., September 1, 2008; 29(17): 2171 - 2179.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. Fraccarollo, P. Galuppo, I. Schmidt, G. Ertl, and J. Bauersachs
Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction
Cardiovasc Res, July 1, 2005; 67(1): 97 - 105.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Widder, T. Behr, D. Fraccarollo, K. Hu, P. Galuppo, P. Tas, C. E Angermann, G. Ertl, and J. Bauersachs
Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent
Cardiovasc Res, July 1, 2004; 63(1): 161 - 167.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.